ARS Pharmaceuticals (SPRY) Return on Sales (2022 - 2026)
ARS Pharmaceuticals (SPRY) posted Return on Sales of 0.04% for Q1 2026, down 172.98% sequentially from 0.02% in Q4 2025, and little changed YoY from 0.04% in Q1 2025.
ARS Pharmaceuticals (SPRY) Return on Sales (2022 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Return on Sales for 5 years, with the latest figure at 0.04% in Q1 2026.
- Quarterly Return on Sales changed 0.0% year-over-year to 0.04% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.05% (down 3.0% YoY) and the FY2025 annual result came in at 0.02%, down 2.0% from the prior year.
- Return on Sales fell to 0.04% in Q1 2026 per SPRY's latest filing, from 0.02% in the prior quarter.
- Over five years, Return on Sales peaked at 0.01% in Q4 2024 and troughed at 53762.25% in Q1 2024.
- A 5-year average of 10219.12% and a median of 0.42% in 2022 frame the typical range for Return on Sales.
- The sharpest annual moves came in 2023 and 2025: Return on Sales sank 3820065 bps in 2023, then surged 5376220 bps in 2025.
- Over 5 years, Return on Sales stood at 0.42% in 2022, then sank by 7366698 bps to 31026.2% in 2023, then jumped by 100 bps to 0.01% in 2024, then slumped by 384 bps to 0.02% in 2025, then tumbled by 173 bps to 0.04% in 2026.
- According to Business Quant data, Return on Sales over the past three periods registered 0.04%, 0.02%, and 0.03% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 0.00% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.00% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.00% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.00% |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | -0.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.03% |
| Mar 31, 2026 | -0.04% |
| Dec 31, 2025 | -0.02% |
| Sep 30, 2025 | -0.03% |
| Jun 30, 2025 | -0.14% |
| Mar 31, 2025 | -0.05% |
| Dec 31, 2024 | 0.01% |
| Sep 30, 2024 | -0.75% |
| Jun 30, 2024 | -1.35% |
| Mar 31, 2024 | -53,762.25% |
| Dec 31, 2023 | -31,026.20% |
| Sep 30, 2023 | -31,027.90% |
| Jun 30, 2023 | -38,200.95% |
| Mar 31, 2023 | -19,703.62% |
| Dec 31, 2022 | -0.42% |
| Sep 30, 2022 | -0.80% |
| Jun 30, 2022 | -0.29% |
| Mar 31, 2022 | -0.17% |